MindMed Declares US$17.0 Million Net Loss, US$105.7 Million Cash Balance For Q2 2022
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial results for Q2 2022. The
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday its financial results for Q2 2022. The
Read moreAn activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder of the company Dr Scott
Read moreIn a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that it’s directors have approved a
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results from the phase 1 clinical
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top collaborators have released positive topline
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced this morning its financial results for 2021. The biotech
Read moreIt’s always a positive sign when a chief financial officer resigns the last business day before annual filings are to
Read moreMind Medicine (NEO: MMED) appears to now be fully under new management. On Friday evening, after the close of markets,
Read moreMind Medicine Inc. (NEO: MMED), more commonly known as MindMed, has recently concluded the phase 1 clinical trial for its
Read moreMind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO this past summer. Classified as
Read more